EventsViruses 2026 – New Horizons in Virology
Published
This submission belongs to the session S2. Antiviral Therapeutics, Vaccines, and Host Defenses of the event Viruses 2026 – New Horizons in Virology
Published date
09 Mar, 2026
Academic Editor
author-avatarEric Freed
Citation
Júlia Amaral Vieira d'Almeida, Diego de Almeida Prado Zannin, Bruna Coelho Sandim, Natasha Marques Cassani, Pedro Paulo Corbi, Ana Carolina Gomes Jardim, Metal Complexation Enhances Amantadine-Derived Schiff Base Inhibition of Zika Virus, in Proceedings of Viruses 2026 – New Horizons in Virology, Barcelona, 11 March–13 March 2026, MDPI: Basel, Switzerland
Share
Email
Facebook
Twitter
LinkedIn

Metal Complexation Enhances Amantadine-Derived Schiff Base Inhibition of Zika Virus

Diego de Almeida Prado Zannin 3
Bruna Coelho Sandim 4
image
image
1. Institute of Bioengineering, University of Tartu, Nooruse 1, 50411 Tartu, Estonia, Brazil
2. Laboratory of Antiviral Research, Institute of Biomedical Science, ICBIM, Federal University of Uberlândia, Uberlândia, MG, Brazil
3. Institute of Chemistry, University of Campinas – UNICAMP, Campinas, SP, Brazil, Brazil
4. Laboratory of Antiviral Research, Institute of Biomedical Science, ICBIM, Federal University of Uberlândia, Uberlândia, MG, Brazil, Brazil
Abstract

Introduction: Zika fever is a disease caused by Orthoflavivirus zikaense (Zika virus, ZIKV), mainly transmitted by mosquitoes of the Aedes genus. The symptoms are classified as dengue-like, however, more severe cases can present neurological disorders, such as Guillain-Barré syndrome and microcephaly in newborns of infected pregnant women. ZIKV belongs to the family Flaviviridae that is characterized by viruses with a positive sense single stranded RNA. However, no vaccines or antiviral drugs are currently available against ZIKV, making the search for compounds with antiviral activity essential. Objective: Evaluate the antiviral activity of a Schiff base derived from amantadine coordinated to cobalt(II) on ZIKV replication. Methods: Cell viability and antiviral assays were conducted to determine the 50% effective concentration (EC₅₀), 50% cytotoxic concentration (CC₅₀), and selectivity index (SI = CC₅₀/EC₅₀). Immunofluorescence assays were used to measure infection levels. Vero E6 cells were infected with the ZIKVPE243 strain at a multiplicity of infection (MOI) of 0.01. Results: The cobalt–Schiff base complex (Co-atdSali) reduced ZIKV infection by more than 90%, while the starting Co(II) salt alone and the free Schiff base (atdSali) used in the synthesis of Co-atdSali reduced infection by 44% and 8%, respectively. The complex also showed strong inhibition of ZIKV replication in the dose–response assay, with a selectivity index (SI) of 14.7, compared with 3.9 for Co(II) salt and 1.6 for atdSali. Conclusion: The Co-atdSali complex exhibits enhanced antiviral activity compared to its free ligands, indicating the potential of metal coordination as a promising approach for developing new antiviral drug candidates against ZIKV.

Keywords
antiviral drugs
Zika virus
metal complex
cobalt(II)
Uncovering bacteriophage–LPS interactions with Gram-negative model membranes
Virological characteristics of SARS-CoV-2-related coronaviruses dynamically circulating in Southeast Asia